Why the study?
It was unknown whether baseline LVMi influences how empagliflozin affects cardiac reverse remodelling in patients with type 2 diabetes and coronary artery disease.
Does empagliflozin reduce left ventricular mass in patients with type 2 diabetes and coronary artery disease, and is this effect influenced by baseline left ventricular mass?
Does empagliflozin reduce left ventricular mass in patients with type 2 diabetes and coronary artery disease, and is this effect influenced by baseline left ventricular mass?
Empagliflozin leads to significant left ventricular mass regression in patients with type 2 diabetes and coronary artery disease specifically when baseline LVMi is elevated (>60 g/m2).
Answers are grounded in this paper and cite their sources.
Higher baseline LVMi may identify patients with greater empagliflozin-associated remodeling; hypothesis-generating and requires prospective confirmation.
Background The cardiovascular (CV) benefits of sodium-glucose transport protein 2 inhibitors have been attributed, in part, to cardiac reverse remodelling. The EMPA-HEART CardioLink-6 study reported that sodium-glucose cotransporter-2 inhibition for 6 months with empagliflozin was associated with a significant reduction in left ventricular mass indexed to body surface area (LVMi). In this sub-analysis, we evaluated whether baseline LVMi may influence how empagliflozin affects cardiac reverse remodelling. Methods A total of 97 patients with type 2 diabetes and coronary artery disease were randomized to empagliflozin (10 mg/d) or matching placebo for 6 months. The study cohort was divided into those whose baseline LVMi was ≤ 60 g/m 2 and those who had a baseline LVMi > 60 g/m 2 . Subgroup comparisons were conducted using a linear regression model adjusted for baseline values (ANCOVA) that included an interaction term between LVMi subgroup and treatment. Results Baseline LVMi was 53.3 g/m 2 (49.2–57.2) and 69.7 g/m 2 (64.2–76.1) for those with baseline ≤ 60 g/m 2 (n = 54) and LVMi > 60 g/m 2 (n = 43) respectively. The adjusted difference of LVMi regression between those randomized to empagliflozin and placebo were − 0.46 g/m 2 (95% CI: −3.44, 2.52, p = 0.76) in the baseline LVMi ≤ 60 g/m 2 subgroup and − 7.26 g/m 2 (95% CI: −11.40, −3.12, p = 0.0011) in the baseline LVMi > 60 g/m 2 subgroup ( p -for-interaction = 0.007). No significant associations were found between baseline LVMi and 6-month change in LV end systolic volume-indexed ( p -for-interaction = 0.086), LV end diastolic volume-indexed ( p -for-interaction = 0.34), or LV ejection fraction ( p -for-interaction = 0.15). Conclusions Patients with higher LVMi at baseline experienced greater LVM regression with empagliflozin.
No takes yet. Share an insight, caveat, or question.
Puar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: